<DOC>
	<DOCNO>NCT02535221</DOCNO>
	<brief_summary>This study propose prove efficacy adjuvant endocrine therapy premenopausal HR positive breast cancer patient non-inferiority adjuvant chemotherapy assess ultrasound response rate .</brief_summary>
	<brief_title>Neoadjuvant Endocrine Therapy Versus Chemotherapy Premenopausal Patients With ER+ &amp; HER2- Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>35 year old ＜age≤55 year old , premenopausal status ( judgement researcher patient recruit ) Histologically confirm primary invasive breast cancer Stage : T2N0M0 ( cT &gt; 2cm , SLNB negative ) , hard proceed breast conserving surgery ( feasible may affect appearance breast ) Histologically confirm HR+ ( ER PR positive , &gt; 50 % cell IHC ) HER2 negative breast cancer pathological evaluation No previous treatment primary breast cancer Without tumor unstable complication uncontrolled infection No contradiction third generation AIs , LHRHa , chemotherapy Attend study voluntarily , sign inform consent . Metastasis disease pathological radiological diagnosis history tumor contradiction third generation AIs , LHRHa , chemotherapy Contradiction adjuvant chemotherapy : serious cardiology cerebral vessel disease , liver kidney disfunction , blood system disease , situation complication suitable adaptable chemotherapy Contradiction proceeding surgery : contradiction anesthesia , large lesion , T4 , lymph node positive situation suitable research : psychological disease , mental disorder , social problem , geographic problem attendance antitumor treatment clinical trial 8 ) reject attend study</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Premenopausal Patients</keyword>
	<keyword>Estrogen Receptor-Positive HER2 negative</keyword>
</DOC>